Short-term Outcomes of Laparoscopic Repair of Paravaginal Defects

Sponsor
Zagazig University (Other)
Overall Status
Completed
CT.gov ID
NCT03962075
Collaborator
(none)
50
1
21.3

Study Details

Study Description

Brief Summary

this study designed To evaluate the efficacy and outcomes of laparoscopic approach for repair of paravaginal defects associated with anterior vaginal wall prolapse.

Condition or Disease Intervention/Treatment Phase
  • Procedure: laparoscopic paravaginal repair
N/A

Detailed Description

This prospective interventional study. designed to evaluate the efficacy and outcomes of laparoscopic approach for repair of paravaginal defects associated with anterior vaginal wall prolapse .fifty participants with cystocele of lateral type offered laparoscopic paravaginal repair. the investigator used a 10mm laparoscope, with video camera, was introduced through the umbilical trocar. Another 5 mm in suprapubic area and two 10 mm trocars in right and left lateral abdominal sides were introduced. The larger trocar was needed to accommodate the passage of needles into the abdomen. Spacing of trocars sufficiently from each other was needed to facilitate laparoscopic suturing. Transperitoneal approach to retropubic space was used. Two to four polypropylene sutures were applied on each side. Sutures were tied with intracorporeal . The study evaluated the following outcomes Operative time, intra-operative blood loss, hospital stay , post-operative urinary symptoms, post-operative pain, fever, haematuria, post-operative vaginal wall prolapse .

Study Design

Study Type:
Interventional
Actual Enrollment :
50 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Short-term Outcomes of Laparoscopic Repair of Paravaginal Defects: A Clinical Trial
Actual Study Start Date :
Aug 1, 2016
Actual Primary Completion Date :
Feb 20, 2018
Actual Study Completion Date :
May 10, 2018

Arms and Interventions

Arm Intervention/Treatment
Other: laparoscopic paravaginal repair

patient enrolled in this arm were offered laparoscopic paravaginal repair by Using a 10mm laparoscope, video camera, was introduced through the umbilical trocar. Another 5 mm in suprapubic area and two 10 mm trocars in right and left lateral abdominal sides were introduced. The larger trocar was needed to accommodate the passage of needles into the abdomen. Spacing of trocars sufficiently from each other was needed to facilitate laparoscopic suturing. Transperitoneal approach to retropubic space was used. Two to four polypropylene sutures were applied on each side. Sutures were tied with intracorporeal technique All cases received diclofenac potassium 100 mg and meperidine hydrochloride 50 mg intramuscular with anesthesia recovery and 12 hours later second dose of diclofenac potassium was given. Also 40-60 mg Enoxaparin was given 6-12 hours postoperatively as subcutaneous injection. Foley's catheter was removed 6 hours postoperative

Procedure: laparoscopic paravaginal repair
Using a 10mm laparoscope, with video camera, was introduced through the umbilical trocar. Another 5 mm in suprapubic area and two 10 mm trocars in right and left lateral abdominal sides were introduced. The larger trocar was needed to accommodate the passage of needles into the abdomen. Spacing of trocars sufficiently from each other was needed to facilitate laparoscopic suturing. Transperitoneal approach to retropubic space was used. Two to four polypropylene sutures were applied on each side. Sutures were tied with intracorporeal technique

Outcome Measures

Primary Outcome Measures

  1. operative time [insertion of the primary tracer ( umbilical trocar )-during the procedure - ends with removing camera telescope]

    time needed for the procedure to be completed

  2. intraoperative blood loss [start with dissection or retropubic space - during the procedure -ends with removing the camera telescope at the end of operation]

    amount of bleeding during the procedure

  3. post-operative pain: Faces Pain Scale [start after patient recovery from anaesthesia - ends after 12 hours]

    assessment of pain using Faces Pain Scale( displaying faces that show how much pain the participant can feel. starting with the face on far left shows no pain as The faces move to the right show more and more pain that ends with the face on the right which shows the worst pain then the participants Point to the face that shows how much they feel pain , Each face has a score 0, 2, 4, 6, 8, or 10, so score "0" = "no pain" and score "10" = "very much pain).

  4. post-operative hematuria [starts observation of urine 1hour after end of operation - ends 24 hours after the starting observation]

    visible red or brown discoloration of urine .

  5. hospital stay [during hospitalization]

    hours needed to keep the patient in hospital post operative

  6. fever [starts after shifting the patient from the recovery room to inpatient ward - end 24 hours after shifting the patient]

    body temperature 38 Celsius or above

Secondary Outcome Measures

  1. post-operative vaginal wall prolapse [starts one week following the procedure - three months after the procedure - six months after the procedure -ends one year after the procedure]

    assessment of the anterior vaginal wall using:Pelvic Organ Prolapse Quantification System .

  2. post-operative abnormal urinary symptoms [starts one week following the procedure - three months after the procedure - six months after the procedure -ends one year after the procedure]

    abnormal urinary symptoms: ( inability to urinate voluntary- pain during micturition - involuntary escape of urine )

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 50 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • female patient with cystocele of lateral type ( paravaginal defect )
Exclusion Criteria:
  • previous retropubic surgery,

  • uterine prolapse,

  • stress urinary incontinence or

  • morbid obesity

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Zagazig University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hossam mohamed, principal investigator, Zagazig University
ClinicalTrials.gov Identifier:
NCT03962075
Other Study ID Numbers:
  • 2765/20-6-2016
First Posted:
May 23, 2019
Last Update Posted:
May 23, 2019
Last Verified:
May 1, 2019
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 23, 2019